Takeda’s global quest for health equity

Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.

By Taren Grom • Dec. 8, 2022

Non-toxic and addiction free: The promise of a new pain med

Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

By Taren Grom • Dec. 1, 2022

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

10 of our most popular articles in 2022

Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.

By Meagan Parrish • Nov. 30, 2022

Woman of the Week: Myriad Genetics’ Nicole Lambert

Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.

By Taren Grom • Nov. 23, 2022

A ‘bold vision’ to prevent diabetes

Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

By Alexandra Pecci • Nov. 15, 2022

The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

By Taren Grom • Nov. 11, 2022

While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

By Michael Gibney • Nov. 8, 2022

The other ‘D’ in DE&I

How companies can work to include people with disabilities into broader equity aims.

By Taren Grom • Nov. 4, 2022

Woman of the Week: City of Hope’s Gulden Mesara

Charged with bridging the 100-year-old research center to its future mission of holistic patient cancer care, Mesara is bringing decades of experience in communications and culture creation.

By Taren Grom • Nov. 2, 2022

While DCTs get all the hype, some industry insiders say the future is a digital hybrid

Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.

By Michael Gibney • Nov. 1, 2022

Tips for tackling trial recruitment and retention woes in oncology

How new tools are helping companies find and keep cancer patients in clinical studies.

By Kelly Bilodeau • Oct. 31, 2022

How does the Inflation Reduction Act affect healthcare?

The Inflation Reduction Act helps support American families by lowering prescription drug prices and reducing overall healthcare costs.

Oct. 31, 2022

Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots

The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.

By Meagan Parrish • Oct. 25, 2022

Checking the box on digital engagement isn’t enough

In a recent study, 50% of healthcare consumers reported that a bad digital experience can ruin the patient journey, while 39% felt that a good digital interaction had a positive influence.

Oct. 24, 2022

What’s keeping pharma leaders up at night

C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.

By Taren Grom • Oct. 21, 2022

5 impactful drug trial failures from the last year

Major recent trial flops and what they mean for companies, patients and the industry.

By Meagan Parrish • Oct. 19, 2022

Woman of the Week: Exscientia’s Charlotte Deane

Is the industry ready for a biologic discovery revolution? Charlotte Deane, chief scientist of biologics AI at Exscientia, thinks so.

By Taren Grom • Oct. 19, 2022

Does your copay program factor in differences across specialties? GoodRx analysis shows it should.

New findings reveal an out-of-pocket cost gap between brand-name and generic prescriptions. To address this gap, GoodRx is partnering with pharmaceutical companies to improve cost transparency and communication between patients and providers.  

Oct. 17, 2022

Robotic pills could open a world of possibilities for the biologics market

As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions. 

By Karissa Waddick • Oct. 13, 2022

Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

After making the leap from academia to the world of biotech, CEO Dr. Amit Etkin is hoping to shift the treatment paradigm for neurological conditions.

By Alexandra Pecci • Oct. 11, 2022

New partnership may give MDMA an edge in the psychedelics space

While LSD and psilocybin steal the spotlight, drug developers are also exploring MDMA for a wide swath of neurological illnesses. 

By Kelly Bilodeau • Oct. 10, 2022

Patient insights data

While there are many sources of real-world evidence, there’s growing interest and focus on capturing patient generated insights to capture a more specific level of understanding for a given therapy.

Oct. 10, 2022

The evolving roles and responsibilities of digital opinion leaders in medical education

In the past, patients entrusted their healthcare providers to provide information about health-related matters.

Oct. 3, 2022

Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success

The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression. 

By Meagan Parrish • Sept. 27, 2022

Why precision medicine could be the next frontier in treating autism

Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.

By Kelly Bilodeau • Sept. 27, 2022